Recent Advances and Emerging Therapies in Medical Dermatology

Conclusions

• The presentation concludes that remibrutinib offers a fast-acting oral BTK-inhibitor option for chronic spontaneous urticaria with strong symptom improvement and a generally manageable safety profile, though mucocutaneous bleeding should be discussed.
• It concludes that icotrokinra provides the first oral IL-23 receptor antagonist for psoriasis with efficacy that is better than deucravacitinib and comparable to ustekinumab, but still below the strongest injectable biologics.
• It concludes that the KNOCKOUT study suggests high-dose intermittent IL-23 blockade may deplete tissue-resident memory T cells and induce prolonged psoriasis remission after only a few doses.
• It concludes that the anti-OX40 strategy is biologically promising but currently undermined by Kaposi sarcoma safety concerns, leading to rocatinlimab withdrawal and greater caution for the class.
• It concludes that rezpegaldesleukin represents a novel immune-tolerance approach in atopic dermatitis, with responses that deepen over time and may allow less frequent maintenance dosing.
• It concludes that upadacitinib appears highly effective for alopecia areata, producing deep hair-regrowth responses with substantial rates of SALT 10 and SALT 0 improvement.
• It concludes that baricitinib has durable five-year efficacy and reassuring long-term safety in alopecia areata, with no major new safety signals emerging.
• It concludes that ritlecitinib also shows progressive long-term benefit in alopecia areata, although its response appears slower and less deep than upadacitinib.
• Overall, the presentation concludes that dermatology is moving toward more oral, mechanism-based therapies that can produce deeper and sometimes more durable disease control than older approaches.
• It concludes that future treatment selection will increasingly depend on shared decision-making that balances efficacy, route of administration, durability, and class-specific safety concerns.